Peripheral Drivers of Heart Failure Progression - The Prospective PEDAL-HF Study

Condition(s) studied

Investigational drug(s) / intervention(s)

Heart Failure network care: Patients will receive three visits within the first three months after randomization for improving heart failure therapy at a cardiologist or the outpatient heart failure clinic

Study summary

PEDAL-HF is a registry-based randomized prospective multicenter study. The investigators plan to include 1000 patients who were recently admitted with acute decompensated heart failure at five tertiary heart clinics in Germany. For the randomised part, 750 patients will be randomized to care within a heart failure network or usual care. The primary endpoint of the randomized trial is change in NT-proBNP from baseline to 6 months of follow-up.

All patients (randomized or not) will be followed for two years.

Eligibility

Primary outcome measure(s)

• Change in NT-proBNP plasma levels between baseline and 6 months visit — 6 months
  Adjusted geometric mean ratio between 6 months visit and baseline visit

Trial sites (1)

More University of Leipzig trials in Germany

Other trials for the same condition